Incidence of Late Haemorrhage After Invasive Gastroenterological Endoscopic Manoeuvre in Patients Treated With Anticoagulants Compared to Non-anticoagulated Patients

Launched by CENTRO CARDIOLOGICO MONZINO · Jun 5, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the risk of late bleeding in patients who have undergone certain endoscopic procedures while on blood-thinning medications, known as anticoagulants. These medications are used to prevent blood clots but may increase the risk of bleeding during and after medical procedures. The trial aims to compare patients who are on anticoagulants with those who are not, to better understand the safety and potential complications associated with these procedures.

To be eligible for this trial, participants must be at least 18 years old and scheduled for an endoscopic procedure, such as an upper gastrointestinal endoscopy, colonoscopy, or other specific types of procedures. However, individuals with certain health conditions, like active cancer in the digestive system or severe bleeding disorders, cannot participate. Participants in the trial can expect close monitoring for any bleeding after their procedure and will help researchers gather important information about the best practices for managing anticoagulant therapy during these medical procedures. This research could ultimately improve safety and care for patients needing these types of treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age \>= 18 years
• • Expected endoscopic manoeuvre among those listed below
• • EGDS ± biopsy/polypectomy
• • Colonoscopy ± biopsy/polypectomy
• • Echoguided endoscopy ± biopsy/polypectomy
• • Double-balloon enteroscopy
• • ERCP (endoscopic retrograde cholangio-pancreatography) ± sphincterotomy
• Exclusion Criteria:
• • Age \< 18 years
• • Known active neoplasms of the gastroenteric tract
• • Gastrointestinal procedures performed as an emergency
• • Patients with an intrinsic haemorrhagic diathesis (e.g. known plateletopenia \< 50,000/mmc)
• • Patients on antiplatelet treatment with clopidogrel or other thienopyridines